Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
G-1 is a selective agonist of the G protein-coupled estrogen receptor (GPER; formerly known as GPR30), distinct from classical estrogen receptors ERα and ERβ. It is primarily a research compound and is not approved as a pharmaceutical for clinical use. G-1 is used in preclinical studies to investigate the biological functions of GPER, including its roles in cell proliferation, cardiovascular function, metabolic regulation, and cancer biology. G-1 demonstrates high specificity for GPER, mediating rapid, non-genomic signaling pathways distinct from those of nuclear estrogen receptors. Users should not confuse G-1 with any pill or product simply marked G1 or G 1, which may refer to entirely different active ingredients (e.g., guanfacine, glycopyrrolate) depending on imprint[3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on G-1.